These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 11857497

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis.
    Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG.
    Urology; 2004 Feb; 63(2):414-8. PubMed ID: 14972513
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma.
    Harden SV, Guo Z, Epstein JI, Sidransky D.
    J Urol; 2003 Mar; 169(3):1138-42. PubMed ID: 12576869
    [Abstract] [Full Text] [Related]

  • 7. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?
    Bernardini S, Miano R, Iori R, Finazzi-Agrò E, Palmieri G, Ballerini S, Angeloni C, Orlandi A, Bellincampi L, Cortese C, Federici G.
    Clin Chim Acta; 2004 Dec; 350(1-2):181-8. PubMed ID: 15530476
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation.
    Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow NH, Grasso M, Wu L, Westra WB, Sidransky D.
    Clin Cancer Res; 2001 Sep; 7(9):2727-30. PubMed ID: 11555585
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
    Chuang CK, Chu DC, Tzou RD, Liou SI, Chia JH, Sun CF.
    Cancer Detect Prev; 2007 Sep; 31(1):59-63. PubMed ID: 17291695
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma.
    Chu DC, Chuang CK, Fu JB, Huang HS, Tseng CP, Sun CF.
    J Urol; 2002 Apr; 167(4):1854-8. PubMed ID: 11912447
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
    Ellinger J, Haan K, Heukamp LC, Kahl P, Büttner R, Müller SC, von Ruecker A, Bastian PJ.
    Prostate; 2008 Jan 01; 68(1):42-9. PubMed ID: 18004747
    [Abstract] [Full Text] [Related]

  • 20. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
    Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Müller SC, von Ruecker A.
    Clin Cancer Res; 2005 Jun 01; 11(11):4097-106. PubMed ID: 15930345
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.